SOAT1 and diffuse large B-cell lymphoma: Moreover, cluster E revealed a potentially druggable GC target, including possible “repurposing” of cerdulatinib, a dual inhibitor of Syk and JAK/STAT signaling in certain types of diffuse large B cell lymphoma cell lines (Ma et al., 2015).